Home/Pipeline/Brivaracetam Oral Solution

Brivaracetam Oral Solution

Epilepsy

ApprovedCommercial Launch PendingANDA

Key Facts

Indication

Epilepsy

Phase

Approved

Status

Commercial Launch Pending

Company

Indoco Remedies

About Indoco Remedies

Founded in 1947, Indoco Remedies has evolved from a trading concern into a $15+ billion market cap pharmaceutical enterprise with a mission to deliver high-quality, affordable medicines globally. Its core strategy is built on vertical integration, combining API synthesis with sophisticated formulation development in complex generics, particularly sterile injectables, ophthalmics, and oral solutions. Recent achievements include multiple USFDA ANDA approvals, successful regulatory inspections with zero observations, and strategic expansion into key international markets like the US and Europe through partnerships and acquisitions.

View full company profile

Therapeutic Areas

CNS / Epilepsy Cardiovascular Anti-infectives Ophthalmology Metabolic Disorders

Other Epilepsy Drugs

Drug	Company	Phase	Status
ADX71149 (mGlu2 PAM)	Addex Therapeutics	Phase 2	Active (with Janssen)
TRV045	Trevena	Phase 1	Active
SAGE-324	Sage Therapeutics	Preclinical	Research
Motpoly XR™	Aucta Pharmaceuticals	Not Specified (Likely Phase 3/NDA)	Active
ADB-104	Adolore BioTherapeutics	Pre-clinical	Active
Not Publicly Disclosed	Cerecin	Phase 2	Active
eTNS Platform	NeuroSigma	Unknown	Active
NPT 2042	NeuroPro Therapeutics	Phase 2	Active
Spritam (levetiracetam)	Aprecia Pharmaceuticals	Approved	Active
Perampanel	Ark Diagnostics	In Development	Active
NeuroAccess Platform	Cordance Medical	Pre-clinical/Research	Active
Epilepsy Program	Current Surgical	Research	Active